Clinical trial
A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients.
NCT00410540 · Alza Corporation, DE, USA, Industry · Completed
Key facts
| NCT number | NCT00410540 |
|---|---|
| Title | A Study of OROS Hydromorphone HCL vs Morphine in Cancer Pain Patients. |
| Official title | A Randomized, Double-Blind, Controlled Trial of Hydromorphone (Immediate and Sustained- Release) vs Morphine (Immediate and Sustained-release) in Cancer Pain |
| Lead sponsor | Alza Corporation, DE, USA, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, Analgesics, Opioid |
| Intervention type | Drug |
| Interventions | OROS hydromorphone HCL, Morphine sulfate |
| Enrollment | 202 |
| Completion | May 1, 2001 |
| First posted | Dec 13, 2006 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: